The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes - PubMed (original) (raw)
Multicenter Study
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Per-Henrik Groop et al. Diabetes. 2009 Jul.
Abstract
Objectives: This study aimed to identify clinical features associated with premature mortality in a large contemporary cohort of adults with type 1 diabetes.
Research design and methods: The Finnish Diabetic Nephropathy (FinnDiane) study is a national multicenter prospective follow-up study of 4,201 adults with type 1 diabetes from 21 university and central hospitals, 33 district hospitals, and 26 primary health care centers across Finland.
Results: During a median 7 years of follow-up, there were 291 deaths (7%), 3.6-fold (95% CI 3.2-4.0) more than that observed in the age- and sex-matched general population. Excess mortality was only observed in individuals with chronic kidney disease. Individuals with normoalbuminuria showed no excess mortality beyond the general population (standardized mortality ratio [SMR] 0.8, 95% CI 0.5-1.1), independent of the duration of diabetes. The presence of microalbuminuria, macroalbuminuria, and end-stage kidney disease was associated with 2.8, 9.2, and 18.3 times higher SMR, respectively. The increase in mortality across each stage of albuminuria was equivalent to the risk conferred by preexisting macrovascular disease. In addition, the glomerular filtration rate was independently associated with mortality, such that individuals with impaired kidney function, as well as those demonstrating hyperfiltration, had an increased risk of death.
Conclusions: An independent graded association was observed between the presence and severity of kidney disease and mortality in a large contemporary cohort of individuals with type 1 diabetes. These findings highlight the clinical and public health importance of chronic kidney disease and its prevention in the management of type 1 diabetes.
Figures
FIG. 1.
Survival plots showing Cox-adjusted survival of individuals with type 1 diabetes from the FinnDiane study, stratified for the presence and severity of albuminuria (A), estimated GFR (B), and the presence and severity of retinopathy (C) at baseline. All figures are adjusted for age; sex; duration of diabetes; body habitus; the presence and extent of macro- and microvascular complications; glycemic, lipid, and blood pressure control; and drug management. The latter figure (C) is not adjusted for the presence and severity of nephropathy, as discussed in the text.
FIG. 2.
Risk of mortality in individuals with type 1 diabetes from the FinnDiane study associated each level of albuminuria and end-stage kidney disease (ESKD). Adjusted hazard ratios with 95% CIs are standardized against individuals with UAE in the normoalbuminuric range (arbitrary value of 1.0). Adjusted SMRs with 95% CIs are provided standardized against the age- and sex-matched Finnish general population (arbitrary value of 1.0).
FIG. 3.
Relationship of estimated GFR to the hazard ratio for mortality in individuals with type 1 diabetes without end-stage kidney disease from the total FinnDiane cohort (A) and in individuals with normoalbuminuria (B), microalbuminuria (C), and macroalbuminuria (D). Dotted line shows point estimate for cubic regression spline adjusted for other predictive variables. Gray area denotes 95% CI.
FIG. 4.
Relationship of A1C to the hazard ratio for mortality in individuals with type 1 diabetes without end-stage kidney disease. Dotted line shows point estimate for the cubic regression spline adjusted for other predictive variables. Gray area denotes 95% CI.
Similar articles
- Arterial Stiffness Predicts Mortality in Individuals With Type 1 Diabetes.
Tynjälä A, Forsblom C, Harjutsalo V, Groop PH, Gordin D; FinnDiane Study Group. Tynjälä A, et al. Diabetes Care. 2020 Sep;43(9):2266-2271. doi: 10.2337/dc20-0078. Epub 2020 Jul 9. Diabetes Care. 2020. PMID: 32647049 - Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria-Separating the Contribution of Early and Late Risks.
Groop PH, Thomas M, Feodoroff M, Forsblom C, Harjutsalo V; FinnDiane Study Group. Groop PH, et al. Diabetes Care. 2018 Apr;41(4):748-754. doi: 10.2337/dc17-1618. Epub 2018 Jan 29. Diabetes Care. 2018. PMID: 29378776 - Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
Harjutsalo V, Thomas MC, Forsblom C, Groop PH; FinnDiane Study Group. Harjutsalo V, et al. Diabetes Obes Metab. 2018 Dec;20(12):2759-2767. doi: 10.1111/dom.13456. Epub 2018 Aug 7. Diabetes Obes Metab. 2018. PMID: 29962015 - Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes.
Nosadini R, Brocco E. Nosadini R, et al. Exp Clin Endocrinol Diabetes. 1997;105 Suppl 2:1-7. doi: 10.1055/s-0029-1211783. Exp Clin Endocrinol Diabetes. 1997. PMID: 9288531 Review. - Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.
Mogensen CE. Mogensen CE. J Intern Med. 2003 Jul;254(1):45-66. doi: 10.1046/j.1365-2796.2003.01157.x. J Intern Med. 2003. PMID: 12823642 Review.
Cited by
- Research hotspots and future trends in lipid metabolism in chronic kidney disease: a bibliometric and visualization analysis from 2004 to 2023.
Wang Y, Liu T, Liu W, Zhao H, Li P. Wang Y, et al. Front Pharmacol. 2024 Sep 3;15:1401939. doi: 10.3389/fphar.2024.1401939. eCollection 2024. Front Pharmacol. 2024. PMID: 39290864 Free PMC article. - Increased incidence of neurodegenerative diseases in Finnish individuals with type 1 diabetes.
Satuli-Autere S, Harjutsalo V, Eriksson MI, Hägg-Holmberg S, Öhman H, Claesson TB, Groop PH, Thorn LM; FinnDiane Study Group. Satuli-Autere S, et al. BMJ Open Diabetes Res Care. 2024 Sep 5;12(4):e004024. doi: 10.1136/bmjdrc-2024-004024. BMJ Open Diabetes Res Care. 2024. PMID: 39242121 Free PMC article. - Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease.
Limonte CP, Lamprea-Montealegre JA, Tuttle KR. Limonte CP, et al. Semin Nephrol. 2024 Mar;44(2):151520. doi: 10.1016/j.semnephrol.2024.151520. Epub 2024 May 5. Semin Nephrol. 2024. PMID: 38705774 Review. - Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.
Piko N, Bevc S, Hojs R, Ekart R. Piko N, et al. Pharmaceuticals (Basel). 2024 Mar 26;17(4):418. doi: 10.3390/ph17040418. Pharmaceuticals (Basel). 2024. PMID: 38675379 Free PMC article. Review. - Transglutaminase 2 in diabetes mellitus: Unraveling its multifaceted role and therapeutic implications for vascular complications.
Ha KS. Ha KS. Theranostics. 2024 Mar 25;14(6):2329-2344. doi: 10.7150/thno.95742. eCollection 2024. Theranostics. 2024. PMID: 38646650 Free PMC article. Review.
References
- Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003; 26: 1258– 1264 - PubMed
- Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992; 41: 836– 839 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical